Cannabis and endogenous cannabinoid systems

Drug and Alcohol Dependence

Volumn 51, Issue 1-2, 1998, Pages 173-187

  Childers, Steven R ^a   Breivogel, Christopher S ^a  

^a WAKE FOREST SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CANNABINOID; CANNABINOID RECEPTOR; CANNABIS; DRONABINOL; GUANINE NUCLEOTIDE BINDING PROTEIN; MORPHINE;

ANTINOCICEPTION; AWARENESS; CANNABIS ADDICTION; COGNITION; DRUG ABUSE; DRUG TOLERANCE; HUMAN; MEMORY; MOOD; MOTOR ACTIVITY; NONHUMAN; PRIORITY JOURNAL; PROTEIN DOMAIN; RECEPTOR BINDING; REVIEW; REWARD; SIGNAL TRANSDUCTION; SOMNOLENCE; TACHYCARDIA;

CANNABIS;

EID: 0032104721     PISSN: 03768716     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0376-8716(98)00075-1     Document Type: Article

References (157)

1. Abadji, V., Lin, S., Taha, G., Griffin, G., Stevenson, L.A., Pertwee, R.G., Makriyannis, A., 1994. (R)-methanandamide: a chiral novel anandamide possessing higher potency and metabolic stability. J. Med. Chem. 37, 1889-1893.
2. Abel, E.L., 1980. Marihuana: The First Twelve Thousand Years. Plenum Press, New York.
3. Abood, M.E., Martin, B.R., 1996. Molecular neurobiology of the cannabinoid receptor. Int. Rev. Neurobiol. 39, 197-221.
4. 9-THC without alteration of cannabinoid receptor binding or mRNA levels in whole brain. Pharmacol. Biochem. Beh. 46, 575-579.
5. Aceto, M.D., Scates, S.M., Lowe, J.A., Martin, B.R., 1995. Cannabinoid precipitated withdrawal by the selective cannabinoid receptor antagonist, SR 141716A. Eur. J. Pharmacol. 282, R1-R2.
6. Adams, I.B., Martin, B.R., 1996. Cannabis: pharmacology and toxicology in animals and humans. Addiction 91, 1585-1614.
7. Adams, I.B., Ryan, W., Singer, M., Thomas, B.F., Compton, D., Razdan, R.K., Martin, B.R., 1995. Evaluation of cannabinoid receptor binding and in vivo activities for anandamide analogs. J. Pharmacol. Exp. Ther. 273, 1172-1181.
8. Alexander, G.E., Crutcher, M.D., 1990. Functional architecture of basal ganglia circuits: neural substrates of parallel processing. Trends Neurosci. 13, 266-271.
9. Arreaza, G., Devane, W.A., Omeir, R.L., Sajnani, G., Kunz, J., Cravatt, B.F., Deutsch, D.G., 1997. The cloned rat hydrolytic enzyme responsible for the breakdown of anandamide also catalyzes its formation via the condensation of arachidonic acid and ethanolamine. Neurosci. Lett. 234, 59-62.
10. Audette, C.A., Burstein, S.H., Doyle, S.A., Hunter, S.A., 1991. G-protein mediation of cannabinoid-induced phospholipase activation. Pharmacol. Biochem. Beh. 40, 559-563.
11. Barth, F., Rinaldi-Carmona, M., Millan, J., Derocq, J.-M., Bouaboula, M., Casellas, P., Shire, D., Breliere, J.-C., Le Fur, G., 1997. SR144528, a potent and selective antagonist of the CB2 receptor. Int. Cann. Res. Soc. Symp. 1997, 11.
12. Bayewitch, M., Avidor-Reiss, T., Levy, R., Barg, J., Mechoulam, R., Vogel, Z., 1995. The peripheral cannabinoid receptor: adenylate cyclase inhibition and G protein coupling. FEBS Lett. 375, 143-147.
13. 9-Tetrahydrocannabinol antagonizes the peripheral cannabinoid receptor-mediated inhibition of adenylyl cyclase. J. Biol. Chem. 271, 9902-9905.
14. Beltramo, M., Stella, N., Calignano, A., Lin, S.Y., Makriyannis, A., Piomelli, D., 1997. Functional role of high-affinity anandamide transport, as revealed by selective inhibition. Science 277, 1094-1097.
15. Bidaut-Russell, M., Devane, W.A., Hewlett, A.C., 1990. Cannabinoid receptors and modulation of cyclic AMP accumulation in the rat brain. J. Neurochem. 55, 21-26.
16. Bouaboula, M., Poinot-Chazel, C., Bourrié, B., Canat, X., Calandra, B., Rinaldi-Carmona, M., Le Fur, G., Casellas, P., 1995. Activation of mitogen-activated protein kinases by stimulation of the central cannabinoid receptor CB1. Biochem. J. 312, 637-641.
17. Bouaboula, M., Poinot-Chazel, C., Marchand, J., Canat, X., Bourrié, B., Rinaldi-Carmona, M., Calandra, B., Le Fur, G., Casellas, P., 1996. Signaling pathway associated with stimulation of CB2 peripheral cannabinoid receptor: involvement of both mitogen-activated protein kinase and induction of Krox-24 expression. 237
18. Bramblett, R.D., Panu, A.M., Ballesteros, J.A., Reggio, P.H., 1995. Construction of a 3D model of the cannabinoid CB1 receptor: determination of helix ends and helix orientation. Life Sci. 56, 1971-1982.
19. Breivogel, C.S., Childers, S.R., 1998. The functional neuroanatomy of brain cannabinoid receptors. In: Rodriguez de Fonseca, F., Navarro, M. (Eds.), Seminars in the Neurosciences: Neurobiology of Cannabinoid Transmission.
20. Breivogel, C.S., Sim, L.J., Childers, S.R., 1997. Regional differences in cannabinoid receptor/G-protein coupling in rat brain. J. Pharmacol. Exp. Ther. 282, 1632-1642.
21. 35S]GTPγS binding to rat cerebellar membranes correlates with agonist-induced decreases in GDP affinity. J. Biol. Chem., in press.
22. 9-tetrahydrocannabinol is a partial agonist of cannabinoid receptors in mouse brain. Eur. J. Pharmacol. 323, R3-R4.
23. Burstein, S., Budrow, J., Debatis, M., Hunter, S.A., Subramanian, A., 1994. Phospholipase participation in cannabinoid-induced release of free arachidonic acid. Biochem. Pharmacol. 48, 1253-1264.
24. Cadas, H., di Tomaso, E., Piomelli, D., 1997. Occurrence and biosynthesis of endogenous cannabinoid precursor. N-arachidonyl phosphatidylethanolamine, in rat brain. J. Neurosci. 17, 1226-1242.
25. Cadas, H., Gaillet, S., Beltramo, M., Venance, L., Piomelli, D., 1996. Biosynthesis of an endogenous cannabinoid precursor in neurons and its control by calcium and cAMP. J. Neurosci. in press.
26. 9-Tetrahydrocannabinol differentially affects sensory-evoked potentials in the rat dentate gyrus. J. Pharmacol. Exp. Ther. 239, 936-940.
27. 9-tetrahydrocannabinol on sensory-evoked discharges of granule cells in the dentate gyrus of behaving rats. J. Pharmacol. Exp. Ther. 239, 941-945.
28. Caulfield, M.P., Brown, D.A., 1992. Cannabinoid receptor agonists inhibit Ca currents in NG108-15 neuroblastoma cells via a pertussis toxin-sensitive mechanism. Br. J. Pharmacol. 106, 231-232.
29. Chalsma, A.L., Boyum, D., 1994. Marijuana Situation Assessment. Washington, D.C., Office of National Drug Control Policy.
30. 9-tetrahydrocannabinol enhances ventral tegmental somatodendritic dopamine levels but not forebrain dopamine levels: evidence for local neural action by marijuana's psychoactive ingredient. Brain Res. 621, 65-70.
31. Childers, S.R., 1997. Opioid receptors: pinning down the opiate targets. Curr. Biol. 7, R695-R697.
32. Childers, S.R., Deadwyler, S.A., 1996. Role of cyclic AMP in the actions of cannabinoid receptors. Biochem. Pharmacol. 52, 819-827.
33. Childers, S.R., Pacheco, M.A., Bennett, B.A., Edwards, T.A., Hampson, R.E., Mu, J., Deadwyler, S.A., 1993. Cannabinoid receptors: G-protein-mediated signal transduction mechanisms. Biochem. Soc. Symp. 59, 27-50.
34. Childers, S.R., Sexton, T., Roy, M.B., 1994. Effects of anandamide on cannabinoid receptors in rat brain membranes. Biochem. Pharmacol. 47, 711-715.
35. Collins, D.R., Pertwee, R.G., Davies, S.N., 1994. The action of synthetic cannabinoids on the induction of long-term potentiation in the rat hippocampal slice. Eur. J. Pharmacol. 259, R7-R8.
36. Collins, D.R., Pertwee, R.G., Davies, S.N., 1995. Prevention by the cannabinoid antagonist, SR141716A, of cannabinoid-mediated blockade of long-term potentiation in the rat hippocampal slice. Br. J. Pharmacol. 115, 869-870.
37. Compton, D., Johnson, M.R., Melvin, L., Martin, B.R., 1992. Pharmacological profile of a series of bicyclic cannabinoid analogues: classification as cannabimimetic agents. J. Pharmacol. Exp. Ther. 260, 201-209.
38. Compton, D.R., Aceto, M.D., Lowe, J., Martin, B.R., 1996. In vivo characterization of a specific cannabinoid receptor antagonist (SR141716A): inhibition of delta 9-tetrahydrocannabinol-induced responses and apparent agonist activity. J. Pharmacol. Exp. Ther. 277, 586-594.
39. Compton, D.R., Rice, K.C., DeCosta, B.R., Razdan, R.K., Melvin, L.S., Johnson, M.R., Martin, B.R., 1993. Cannabinoid structure-activity relationships: correlation of receptor binding and in vivo activities. J. Pharmacol. Exp. Ther. 265, 218-226.
40. Cook, S.A., Welch, S.P., Lichtman, A.H., Martin, B.R., 1995. Evaluation of cAMP involvement in cannabinoid-induced antinociception. Life Sci. 56, 2049-2056.
41. Costa, B., Parolaro, D., Colleoni, M., 1996. Chronic cannabinoid, CP-55,940, administration alters biotransformation in the rat. Eur. J. Pharmacol. 313, 17-24.
42. Cravatt, B.F., Giang, D.K., Mayfield, S.P., Boger, D.L., Lerner, R.A., Gilula, N.B., 1996. Molecular characterization of an enzyme that degrades neuromodulatory fatty-acid amides. Nature 384, 83-87.
43. Deadwyler, S.A., Hampson, R.E., Bennett, B.A., Edwards, T.A., Mu, J., Pacheco, M.A., Ward, S.J., Childers, S.R., 1993. Cannabinoids modulate potassium current in cultured hippocampal neurons. Recept. Channels 1, 121-134.
44. Deadwyler, S.A., Hampson, R.E., Childers, S.R., 1995. Functional significance of cannabinoid receptors, in brain. In: Pertwee, R. (Ed.), Cannabinoid Receptors. Academic Press, San Diego, CA., pp. 205-231
45. Deadwyler, S.A., Hampson, R.E., Mu, J., Whyte, A., Childers, S.R., 1995b. Cannabinoids modulate voltage-sensitive potassium A-current in hippocampal neurons via a cAMP-dependent process. J. Pharmacol. Exp. Ther. 273, 734-743.
46. Deadwyler, S.A., Heyser, C.J., Hampson, R.E., 1995c. Complete adaptation to the memory disruptive effects of delta-9-THC following 35 days of exposure. Neurosci. Res. Comm. 17, 9-18.
47. Deutsch, D.G., Chin, S.A., 1993. Enzymatic synthesis and degradation of anandamide, a cannabinoid receptor agonist. Biochem. Pharmacol. 46, 791-796.
48. Deutsch, D.G., Lin, S., Hill, W.A., Morse, K.L., Salehani, D., Arreaza, G., Omeir, R.L., Makriyannis, A., 1997a. Fatty acid sulfonyl fluorides inhibit anandamide metabolism and bind to the cannabinoid receptor. Biochem. Biophys. Res. Commun. 231, 217-221.
49. Deutsch, D.G., Omeir, R., Arreaza, G., Salehani, D., Prestwich, G.D., Huang, Z., Hewlett, A., 1997b. Methyl arachidonyl fluorophosphonate: a potent irreversible inhibitor of anandamide amidase. Biochem. Pharmacol. 53, 255-260.
50. Devane, W.A., Dysarz, F.A.I., Johnson, M.R., Melvin, L.S., Howlett, A.C., 1988. Determination and characterization of a cannabinoid receptor in rat brain. Mol. Pharmacol. 34, 605-613.
51. Devane, W.A., Hanus, L., Breuer, A., Pertwee, R.G., Stevenson, L.A., Griffin, G., Gibson, D., Mandelbaum, A., Etinger, A., Mechoulam, R., 1992. Isolation and structure of a brain constituent that binds to the cannabinoid receptor. Science 258, 1946-1949.
52. Dewey, W.L., 1986. Cannabinoid pharmacology. Pharmacol. Rev. 38, 151-178.
53. Di Chiara, G., Imperato, A., 1988. Drugs abused by humans preferentially increase synaptic dopamine concentrations in the mesolimbic system of freely moving rats. Proc. Natl. Acad. Sci. USA 85, 5274-5278.
54. Dill, J.A., Hewlett, A.C., 1988. Regulation of adenylate cyclase by chronic exposure to cannabimimetic drugs. J. Pharmacol. Exp. Ther. 244, 1157-1163.
55. Evans, D.M., Lake, J.T., Johnson, M.R., Howlett, A.C., 1994. Endogenous cannabinoid receptor binding activity released from rat brain slices by depolarization. J. Pharmacol. Exp. Ther. 268, 1271-1277.
56. Fan, F., Tao, Q., Abood, M.E., Martin, B.R., 1996. Cannabinoid receptor down-regulation without alteration of the inhibitory effect of CP 55,940 on adenylyl cyclase in the cerebellum of CP 55,940-tolerant mice. Brain Res. 706, 13-20.
57. 2 receptors. Mol. Pharmacol. 48, 443-450.
58. Fernando, S.R., Pertwee, R.G., 1997. Evidence that methyl arachidonyl fluorophosphonate is a irreversible cannabinoid receptor antagonist. Br. J. Pharmacol. 121, 1-5.
59. 9-Tetrahydrocannabinol excites rat VTA dopamine neurons through activation of cannabinoid CB1 but not opioid receptors. Neurosci. Lett. 226, 159-162.
60. Gaoni, Y., Mechoulam, R., 1964. Isolation, structure, and partial synthesis of an active constituent of hashish. J. Am. Chem. Soc. 86, 1646-1647.
61. Gessa, G.L., Mascia, M.S., Casu, M.A., Carta, G., 1997. Inhibition of hippocampal acetylcholine release by cannabinoids: reversal by SR 141716A. Eur. J. Pharmacol. 327, R1-R2.
62. Gifford, A.N., Ashby, C.R.J., 1996. Electrically evoked acetylcholine release from hippocampal slices is inhibited by the cannabinoid agonist, WIN 55212-2, and is potentiated by the cannabinoid antagonist, SR 141716A. J. Pharmacol. Exp. Ther. 277, 1431-1436.
63. Gifford, A.N., Gardner, E.L., Ashby, C.R.J., 1997. The effect of intravenous administration of delta-9-tetrahydrocannabinol on the activity of A10 dopamine neurons recorded in vivo in anesthetized rats. Neuropsychobiology 36, 96-99.
64. Glass, M., Dragunow, M., Faull, R.L.M., 1997. Cannabinoid receptors in the human brain: a detailed anatomical and quantitative autoradiographic study in the fetal, neonatal and adult human brain. Neuroscience 77, 299-318.
65. s linkage to the CB1 receptor. J. Neurosci. 17, 5327-5333.
66. Hampson, R.E., Evans, G.J.O., Mu, J., Zhuang, S., King, V.C., Childers, S.R., Deadwyler, S.A., 1995. Role of cyclic AMP dependent protein kinase in cannabinoid receptor modulation of potassium 'A-current' in cultured rat hippocampal neurons. Life Sci. 56, 2081-2088.
67. Henry, D.J., Chavkin, C., 1995. Activation of inwardly rectifying potassium channels (GIRK1) by co-expressed rat brain cannabinoid receptors in Xenopus oocytes. Neurosci. Lett. 186, 91-94.
68. Herkenham, M., Lynn, A.B., de Costa, B.R., Richfield, E.K., 1991a. Neuronal localization of cannabinoid receptors in the basal ganglia of the rat. Brain Res. 547, 267-274.
69. Herkenham, M., Lynn, A.B., Johnson, M.R., Melvin, L.S., de Costa, B.R., Rice, K.C., 1991b. Characterization and localization of cannabinoid receptors in rat brain: a quantitative in vitro autoradiographic study. J. Neurosci. 11, 563-583.
70. Herkenham, M., Lynn, A.B., Little, M.D., Johnson, M.R., Melvin, L.S., De Costa, B.R., Rice, K.C., 1990. Cannabinoid receptor localization in brain. Proc. Natl. Acad. Sci. USA 87, 1932-1936.
71. Heyser, C.J., Hampson, R.E., Deadwyler, S.A., 1993. Effects of delta-9-tetrahydrocannabinol on delayed match to sample performance in rats: Alterations in short-term memory associated with changes in task specific firing of hippocampal cells. J. Pharmacol. Exp. Ther. 264, 294-307.
72. Hillard, C.J., Harris, R.A., Bloom, A.S., 1985. Effects of the cannabinoids on physical properties of brain membranes and phospholipid vesicles: fluorescence studies. J. Pharmacol. Exp. Ther. 232, 579-588.
73. Hohmann, A.G., Martin, W.J., Tsou, K., Walker, J.M., 1995. Inhibition of noxious stimulus-evoked activity of spinal cord dorsal horn neurons by the cannabinoid WIN 55,212-2. Life Sci. 56, 2111-2118.
74. Hollister, L.E., 1986. Health aspects of cannabis. Pharmacol. Rev. 38, 1-20.
75. Hollister, L.E., Gillespie, H.K., Ohlsson, A., Lindgren, J.E., Wahlen, A., Agurell, S., 1981. Do plasma concentrations of delta 9-tetrahydrocannabinol reflect the degree of intoxication? J. Clin. Pharmacol. 21, 171S-177S.
76. 35S]GTPγS binding in the mouse brain. Eur. J. Pharmacol. 321, R1-R3.
77. Houston, D.B., Howlett, A.C., 1993. Solubilization of the cannabinoid receptor from rat brain and its functional interaction with guanine nucleotide-binding proteins. Mol. Pharmacol. 43, 17-22.
78. Howlett, A.C., 1984. Inhibition of neuroblastoma adenylyl cyclase by cannabinoid and nantradol compounds. Life Sci. 35, 1803-1810.
79. Howlett, A.C., 1985. Cannabinoid inhibition of adenylate cyclase: biochemistry of the response in neuroblastoma cell membranes. Mol. Pharmacol. 27, 429-436.
80. Howlett, A.C., 1995. Pharmacology of cannabinoid receptors. Ann. Rev. Pharmacol. Toxicol. 35, 607-634.
81. Howlett, A.C., Fleming, R.M., 1984. Cannabinoid inhibition of adenylate cyclase: pharmacology of the response in neuroblastoma cell membranes. Mol. Pharmacol. 26, 532-538.
82. i in the inhibition of adenylate cyclase by cannabimimetic drugs. Mol. Pharmacol. 29, 307-313.
83. Jackson, A.L., Murphy, L.L., 1997. Role of the hypothalamic-pituitary-adrenal axis in the suppression of luteinizing hormone release by delta-9-tetrahydrocannabinol. Neuroendocrinology 65, 446-452.
84. Jansen, E.M., Haycock, D.A., Ward, S.J., Seybold, V.S., 1992. Distribution of cannabinoid receptors in rat brain determined with aminoalkylindoles. Brain Res. 575, 93-102.
85. 9-Tetrahydrocannabinol increases prefrontal cortical catecholaminergic utilization and impairs spatial working memory in the rat: blockade of dopaminergic effects with HA966. Neuropsychopharmacology 16, 426-432.
86. Johnson, M.R., Melvin, L.S., 1986. The discovery of nonclassical cannabinoid analgetics. In: Mechoulam, R. (Ed.), Cannabinoids as Therapeutic Agents. CRC Press, Boca Raton, pp. 121-145
87. Kaminski, N.E., Abood, M.E., Kessler, F.K., Martin, B.R., Schatz, A.R., 1992. Identification of a functionally relevant cannabinoid receptor on mouse spleen cells that is involved in cannabinoid-mediated immune modulation. Mol. Pharmacol. 42, 736-742.
88. Kirby, M.T., Hampson, R.E., Deadwyler, S.A., 1995. Cannabinoids selectively decrease paired-pulse perforant path synaptic potentials in the dentate gyrus in vitro. Brain Res. 688, 114-120.
89. Kuster, J., Stevenson, J., Ward, S., D'Ambra, T., Haycock, D., 1993. Aminoalkylindole binding in rat cerebellum: selective displacement by natural and synthetic Cannabinoids. J. Pharmacol. Exp. Ther. 264, 1352-1363.
90. 1 receptor. Eur. J. Pharmacol. 334, R1-R2.
91. Lichtman, A.H., Cook, S.A., Martin, B.R., 1996. Investigation of brain sites mediating cannabinoid-induced antinociception in rats: evidence supporting periaqueductal gray involvement. J. Pharmacol. Exp. Ther. 276, 585-593.
92. Lichtman, A.H., Martin, B.R., 1991. Spinal and supraspinal components of cannabinoid-induced antinociception. J. Pharmacol. Exp. Ther. 258, 517-523.
93. Mackie, K., Devane, W.A., Hille, B., 1993. Anandamide, an endogenous cannabinoid, inhibits calcium currents as a partial agonist in N18 neuroblastoma cells. Mol. Pharmacol. 44, 498-503.
94. Mackie, K., Hille, B., 1992. Cannabinoids inhibit N-type calcium channels in neuroblastoma-glioma cells. Proc. Natl. Acad. Sci. USA 89, 3825-3829.
95. Mackie, K., Lai, Y., Westenbroek, R., Mitchell, R., 1995. Cannabinoids activate an inwardly rectifying potassium conductance and inhibit Q-type calcium currents in AtT20 cells transfected with rat brain cannabinoid receptor. J. Neurosci. 15, 6552-6561.
96. Mailleux, P., Vanderhaeghen, J.-J., 1992. Distribution of neuronal cannabinoid receptor in the adult rat brain: a comparative receptor binding radioautography and in situ hybridization histochemistry. Neuroscience 48, 655-668.
97. Maneuf, Y.P., Brotchie, J.M., 1997. Paradoxical action of the cannabinoid WIN 55,212-2 in stimulated and basal cyclic AMP accumulation in rat globus pallidus slices. Br. J. Pharmacol. 120, 1397-1398.
98. Maneuf, Y.P., Crossman, A.R., Brotchie, J.M., 1996a. Modulation of GABAergic transmission in globus pallidus by the synthetic cannabinoid WIN 55,212-2. Synapse 22, 382-385.
99. 9-tetrahydrocannabinol reduces γ-aminobutyric acid uptake in the globus pallidus. Eur. J. Pharmacol. 308, 161-164.
100. Martin, W.J., Hohmann, A.G., Walker, J.M., 1996. Suppression of noxious stimulus-evoked activity in the ventral posterolateral nucleus of the thalamus by a cannabinoid agonist: correlation between electrophysiological and antinociceptive effects. J. Neurosci. 16, 6601-6611.
101. Martin, W.J., Lsi, N.K., Patrick, S.L., Tsou, K., Walker, J.M., 1993. Antinociceptive actions of cannabinoids following intraventricular administration in rats. Brain Res. 629, 300-304.
102. Martin, W.J., Patrick, S.L., Coffin, P.O., Tsou, K., Walker, J.M., 1995. An examination of the central sites of action of cannabinoid-induced antinociception in the rat. Life Sci. 56, 2103-2109.
103. Matsuda, L.A., Lolait, S.J., Brownstein, M.J., Young, A.L., Bonner, T.I., 1990. Structure of a cannabinoid receptor and functional expression of the cloned cDNA. Nature 346, 561-564.
104. Mechoulam, R., Ben-Shabat, S., Hanus, L., Ligumsky, M., Kaminski, N.B., Schatz, A.R., Gopher, A., Almog, S., Martin, B.R., Compton, D.R., 1995. Identification of an endogenous 2-monoglyceride, present in canine gut, that binds to cannabinoid receptors. Biochem. Pharmacol. 50, 83-90.
105. Melvin, L.S., Milne, G.M., Johnson, M.R., Subramaniam, B., Wilken, G.H., Howlett, A.C., 1993. Structure-activity relationships for cannabinoid receptor binding and analgesic activity: studies of bicyclic cannabinoid analogs. Mol. Pharmacol. 44, 1008-1015.
106. Miller, A.S., Walker, J.M., 1996. Electrophysiological effects of a cannabinoid on neural activity in the globus pallidus. Eur. J. Pharmacol. 304, 29-35.
107. Mu, J., Hampson, R.E., Zhuang, S.-Y., King, V.C., Deadwyler, S.A., 1995. SR141716A blocks cannabinoid modulation of potassium A-current in cultured hippocampal neurons. Soc. Neurosci. Abst. 21, 1832.
108. Munro, S., Thomas, K.L., Abu-Shaar, M., 1993. Molecular characterization of a peripheral receptor for cannabinoids. Nature 365, 61-65.
109. Norwicky, A.V., Teyler, T.J., Vardaris, R.M., 1987. The modulation of long-term potentiation by delta-9-tetrahydrocannabinol in the rat hippocampus, in vitro. Brain Res. Bull. 19, 663.
110. Onaivi, E.S., Chakrabarti, A., Chaudhuri, G., 1996. Cannabinoid receptor genes. Prog. Neurobiol. 48, 275-305.
111. Oviedo, A., Glowa, J., Herkenham, M., 1993. Chronic cannabinoid administration alters cannabinoid receptor binding in rat brain: a quantitative autoradiographic study. Brain Res. 616, 293-302.
112. Pacheco, M., Childers, S.R., Arnold, R., Casiano, F., Ward, S.J., 1991. Aminoalkylindoles: actions on specific G-protein-linked receptors. J. Pharmacol. Exp. Ther. 257, 170-183.
113. Pacheco, M., Ward, S.J., Childers, S.R., 1993. Identification of cannabinoid receptors in cultures of rat cerebellar granule cells. Brain Res. 603, 102-110.
114. Pacheco, M.A., Ward, S.J., Childers, S.R., 1994. Differential requirements of sodium for coupling of cannabinoid receptors to adenylyl cyclase in rat brain membranes. J. Neurochem. 62, 1773-1782.
115. Pertwee, R.G., 1988. The central pharmacology of psychotropic cannabinoids. Pharmacol. Therapeut. 36, 189-261.
116. Pertwee, R.G., 1997. Pharmacology of cannabinoid CB1 and CB2 receptors. Pharmacol. Therapeut. 74, 129-180.
117. Pertwee, R.G., Stevenson, L.A., Griffin, G., 1993. Cross-tolerance between delta-9-tetrahydrocannabinol and the cannabimimetic agents, CP 55,940, WIN 55,212-2 and anandamide. Br. J. Pharmacol. 110, 1483-1490.
118. Pertwee, R.G., Wickens, A.P., 1991. Enhancement by chlordiazepoxide of catalepsy induced in rats by intravenous or intrapallidal injections of enantiomeric cannabinoids. Neuropharmacology 30, 237-244.
119. Randall, M.D., Alexander, S.P.H., Bennett, T., Boyd, E.A., Fry, J.R., Gardiner, S.M., Kemp, P.A., McCulloch, A.I., Kendall, D.A., 1996. An endogenous cannabinoid as an endothelium-derived vasorelaxant. Biochem. Biophys. Res. Commun. 229, 114-120.
120. Reggio, P.H., Wang, T., Brown, A.E., Fleming, D.N., Seltzman, H.H., Griffin, G., Pertwee, R.G., Compton, D.R., Abood, M.E., Martin, B.R., 1997. Importance of the C-1 substituent in classical cannabinoids to CB2 receptor selectivity: synthesis and characterization of a series of O,2-propano-delta 8-tetrahydrocannabinol analogs. J. Med. Chem. 40, 3312-3318.
121. Rinaldi-Carmona, M., Earth, F., Heaulme, M., Shire, D., Calandra, B., Congy, C., Martinez, S., Maruani, J., Neliat, G., Caput, D., Ferrara, P., Soubrie, P., Breliere, J.C., Le Fur, G., 1994. SR141716A, a potent and selective antagonist of the brain cannabinoid receptor. FEBS Lett. 350, 240-244.
122. Rodríguez de Fonseca, F., Carrera, M.R.A., Navarro, M., Koob, G.F., Weiss, F., 1997. Activation of corticotropin-releasing factor in the limbic system during cannabinoid withdrawal. Science 276, 2050-2054.
123. Rodríguez de Fonseca, F., Fernández-Ruiz, J.J., Murphy, L., Eldridge, J.C., Steger, R.W., Bartke, A., 1991. Effects of delta-9-tetrahydrocannabinol exposure on adrenal medullary function: evidence of an acute effect and development of tolerance in chronic treatments. Pharmacol. Biochem. Beh. 40, 593-598.
124. 9-tetrahydrocannabinol treatment. Pharmacol. Biochem. Beh. 47, 33-40.
125. 9-tetrahydrocannabinol. Pharmacol. Biochem. Beh. 51, 731-737.
126. 9-tetrahydrocannabinol on cannabinoid receptor binding and mRNA levels in several rat brain regions. Mol. Brain Res. 46, 100-108.
127. Rubino, T., Massi, P., Patrini, G., Venier, I., Giagnoni, G., Parolaro, D., 1994. Chronic CP-55,940 alters cannabinoid receptor mRNA in the rat brain: an in situ hybridization study. NeuroReport 5, 2493-2496.
128. Sañudo-Peña, M.C., Walker, J.M., 1997. Role of the subthalamic nucleus in cannabinoid actions in the substantia nigra of the rat. J. Neurophysiol. 77, 1635-1638.
129. Sasaki, T., Chang, M.C.J., 1997. N-arachidonylethanolamine (anandamide) formation from N-arachidonylphosphatidylethanolamine in rat brain membranes. Life Sci. 61, 1803-1810.
130. 1 receptor-mediated inhibition of noradrenaline release in the human and guinea-pig hippocampus. Naunyn-Schmiedeberg's Arch. Pharmacol. 356, 583-589.
131. 35S]GTPγS binding in rat thalamus and cultured cell lines: Signal transduction mechanisms underlying agonist efficacy. Mol. Pharmacol. 51, 87-96.
132. 35S]thio)triphosphate binding in rat brain membranes. Life Sci. 59, 659-668.
133. Shen, M., Piser, T.M., Seybold, V.S., Thayer, S.A., 1996. Cannabinoid receptor agonists inhibit glutamatergic synaptic transmission in rat hippocampal cultures. J. Neurosci. 16, 4322-4334.
134. Shire, D., Carillon, C., Kaghad, M., Calandra, B., Rinaldi-Carmona, M., Le Fur, G., Caput, D., Ferrara, P., 1995. An amino-terminal variant of the central cannabinoid receptor resulting from alternative splicing. J. Biol. Chem. 270, 3726-3731.
135. 9-tetrahydrocannabinol-evoked arachidonic acid mobilization and blockade by SR141716A. Biochem. Pharmacol. 51, 669-676.
136. Showalter, V.M., Compton, D.R., Martin, B.R., Abood, M.E., 1996. Evaluation of binding in a transfected cell line expressing a peripheral cannabinoid receptor (CB2): identification of cannabinoid receptor subtype selective ligands. J. Pharmacol. Exp. Ther. 278, 989-999.
137. 35S]GTPγS autoradiography in rat brain. J. Neurosci. 16, 8057-8066.
138. 35S]thio]-triphosphate binding. Proc. Natl. Acad. Sci. USA 92, 7242-7246.
139. Sim, L.J., Selley, D.E., Xiao, R., Childers, S.R., 1996b. Differences in G-protein activation by mu and delta opioid, and cannabinoid, receptors in rat striatum. Eur. J. Pharmacol. 307, 95-107.
140. Skaper, S.D., Buriani, A., Dal Toso, R., Petrelli, L., Romanello, S., Facci, L., Leon, A., 1996. The ALIAmide palmitoylethanolamide and cannabinoids, but not anandamide, are protective in a delayed postglutamate paradigm of excitotoxic death in cerebellar granule cells. Proc. Natl. Acad. Sci. USA 93, 3984-3989.
141. Slipetz, D.M., O'Neill, G.P., Favreau, L., Dufresne, C., Gallant, M., Gareau, Y., Guay, D., Labelle, M., Metters, K.M., 1995. Activation of the human peripheral cannabinoid receptor results in inhibition of adenylyl cyclase. Mol. Pharmacol. 48, 352-361.
142. 9-tetrahydrocannabinol-induces analgesia. Brain Res. 578, 8-12.
143. 9-tetrahydrocannabinol and kappa opioids in mice. J. Pharmacol. Exp. Ther. 268, 1382-1387.
144. Stella, N., Schweitzer, P., Piomelli, D., 1997. A second endogenous cannabinoid that modulates long-term potentiation. Nature 388, 773-778.
145. Sugiura, T., Kondo, S., Sukagawa, A., Nakane, S., Shinoda, A., Itoh, K., Yamashita, A., Waku, K., 1995. 2-Arachidonoylglycerol: a possible endogenous cannabinoid receptor ligand in brain. Biochem. Biophys. Res. Commun. 215, 89-97.
146. 1 opioid receptor mechanism. Science 276, 2048-2050.
147. Terranova, J.-P., Michaud, J.-C., Le Fur, G., Soubrié, P., 1995. Inhibition of long-term potentiation in rat hippocampal slice by anandamide and WIN 55212-2: reversal by SR141716 A, a selective antagonist of CB1 cannabinoid receptors. Naunyn-Schmiedeberg's Arch. Pharmacol. 352, 576-579.
148. Thomas, B.F., Adams, I.B., Mascarella, S.W., Martin, B.R., Razdan, R.K., 1996. Structure-activity analysis of anandamide analogs: relationship to a cannabinoid pharmacophore. J. Med. Chem. 39, 471-479.
149. Thomas, B.F., Compton, D.R., Martin, B.R., Semus, S.F., 1991. Modeling the cannabinoid receptor: a three-dimensional quantitative structure-activity analysis. Mol. Pharmacol. 40, 656-665.
150. 9-tetrahydrocannabinol precipitated by a cannabinoid receptor antagonist. Eur. J. Pharmacol. 280, R13-R15.
151. Ward, S.J., Baizman, E., Bell, M., Childers, S., D'Ambra, T., Eissenstat, M., Estep, K., Haycock, D., Howlett, A., Luttinger, D., Miller, M., Pacheco, M., 1990. Aminoalkylindoles (AAIs): a new route to the cannabinoid receptor? NIDA Res. Monographs 105, 425-426.
152. Welch, S.P., 1993. Modulation of cannabinoid-induced antinociception by norbinaltorphimine, but not N,N-diallyl-tyrosine-aibphenylalanine-leucine, ICI 174,864 or naloxone in mice. J. Pharmacol. Exp. Ther. 265, 633-640.
153. Welch, S.P., Thomas, C., Patrick, G.S., 1995. Modulation of cannabinoid-induced antinociception after intracerebroventricular versus intrathecal administration to mice: possible mechanisms for interaction with morphine. J. Pharmacol. Exp. Ther. 272, 310-321.
154. White, R., Hiley, C.R., 1997. A comparison of EDHF-mediated and anandamide-induced relaxations in the rat isolated mesenteric artery. Br. J. Pharmacol. 122, 1573-1584.
155. Wiley, J., Balster, R., Martin, B., 1995. Discriminative stimulus effects of anandamide in rats. Eur. J. Pharmacol. 276, 49-54.
156. Xie, X.Q., Melvin, L.S., Makriyannis, A., 1996. The conformational properties of the highly selective cannabinoid receptor ligand CP-55,940. J. Biol. Chem. 271, 10640-10647.
157. 9-THC on the expression of cannabinoid (CB1) receptor mRNA in different rat brain regions, submitted.